a stronger push to offer drug therapy for primary prevention of breast cancer in higher-risk women
You'll see a stronger push to offer drug therapy for primary prevention of breast cancer in higher-risk women.
Tamoxifen and raloxifene are approved for prevention in women with a 5-year risk of breast cancer ≥ 1.66%...about the risk of an average woman over 60.
But age alone usually isn't enough to start drug therapy. Benefits generally don't outweigh risks unless the woman also has a family history of breast cancer, atypical hyperplasia, or other risks.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote